Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Pupils have been seen urinating in the playground at the end of the school day - apparently with the consent of their parents.
The Welsh government appeared to poke fun at Health Secretary Jeremy Hunt by offering a "warm welcome" to junior doctors working in England.
As Madeira attempts to prevent the Zika virus from establishing a presence, one woman is at the forefront of its efforts.